PharmaTher Holdings Ltd. develops specialty pharmaceutical platforms centered on microneedle drug delivery. Company updates focus on PharmaPatch™ product programs for ketamine, psychedelics, GLP-1 drugs and therapeutic peptides, along with PatchPrint™, its automated tabletop microneedle patch 3D printer designed to support end-to-end patch manufacturing.
Recurring news themes include U.S. patent applications for patch manufacturing and peptide formulations, expansion of the PharmaPatch™ platform into new drug categories, regulatory and policy developments affecting ketamine, psychedelics and peptides, and the company's retained economic participation tied to its previously approved and sold U.S. generic ketamine ANDA.
PharmaTher (PHRRF) is developing personalized oral peptide products led by colon-targeted KPV and BPC-157 for a conditional U.S. compounding pathway. The portfolio uses its M3DICINES pharmaceutical 3D-printing platform and Craft Health's CORR3CT delivery technology. It also includes a BPC-157 chewable or orally disintegrating tablet for the upper gastrointestinal tract.
PharmaTher targets near-term commercialization with healthcare companies, telehealth platforms and pharmacies, with initial development planned at PD Labs, its U.S. Center of Excellence. The HHS policy is scheduled for publication on October 30, 2026; KPV and BPC-157 are the only two of six covered peptides included for oral use. Conditions include documented adequate human oral bioavailability. Neither peptide is FDA-approved. The lead target is left-sided ulcerative colitis; the colon-delivery study used budesonide in a simulated colon, not these peptides in patients.
PharmaTher (PHRRF) submitted FDA applications for Orphan Drug and Rare Pediatric Disease designations for creatine monohydrate to treat GAMT deficiency.
The company is developing 3D-printed, orally dissolvable mini-tablets or pellets for the inherited disorder, which has no FDA-approved treatment. Patients currently use lifelong supplement-grade or compounded creatine. PharmaTher expects decisions on both designation requests and a pre-IND meeting, a discussion with FDA before an investigational drug application, in Q1 2027.
Orphan designation could provide seven years of U.S. market exclusivity upon approval. The program could also qualify for a transferable priority review voucher upon approval; recent vouchers have sold for US$150–200 million. The voucher program runs through September 30, 2029. Neither designation nor a voucher has been granted.
PharmaTher (PHRRF) launched its M3DICINES National Network Program to establish qualified sites for locally producing personalized and short-supply medicines.
The program starts with U.S. 503A compounding pharmacies and is designed to expand to hospitals, contract manufacturers and government facilities using CraftMake pharmaceutical 3D printers. Sites must complete installation, qualification and training before producing medicines. PharmaTher plans to demonstrate its proposed emergency-preparedness node network within the next 12 months and pursue readiness contracts with the U.S. Administration for Strategic Preparedness and Response and Defence Research and Development Canada. Government readiness contracts remain contingent on awards.
PharmaTher (PHRRF) outlined its 3D-printed medicines strategy, targeting up to 50 CraftMake placements over the next 12 months. Its exclusive North American distribution rights cover Craft Health's pharmaceutical printing platform. PERSONALIZ3D has been renamed M3DICINES, and a new corporate website has launched.
The company plans initial printer orders and first proprietary 503A compounded-product launches in Q4 2026, followed by a telehealth ketamine dissolvable tablet in Q1 2027. Rare pediatric designation applications are planned for October 2026, an FDA pre-IND meeting for Q1 2027 and a new drug application for Q4 2028. Other plans include partner services and an emergency printing network. Its ketamine ANDA, sold in December 2025, could generate more than US$25 million over time, subject to commercial performance; payments are expected to begin in Q1 2027.
PharmaTher (PHRRF) has entered an agreement with Craft Health to exclusively distribute its CraftMake pharmaceutical 3D printing platform in North America. The rights cover printers, software, printable formulations, consumables and service across compounding pharmacies, telehealth companies, hospitals, pharmaceutical businesses, and research and government institutions. PharmaTher plans initial platform orders in Q4-2026 to support its rollout.
The agreement provides the production platform for PharmaTher's PERSONALIZ3D initiatives, including personalized peptide and ketamine products, a rare pediatric disease program, and emergency medical countermeasures. PharmaTher also plans contract development and manufacturing services, white-label products sold under customers' brands, and formulation licensing. The company expects installed systems to generate recurring revenue from software, materials, consumables and services.
PharmaTher (CSE: PHRM, OTCQB: PHRRF) announced a collaboration selecting Prescription Dispensing Laboratories (PD Labs), a national Section 503A compounding pharmacy in Cedar Park, Texas, as the U.S. Center of Excellence for its telehealth and pharmaceutical 3D-printing platform, PERSONALIZ3D™.
This completes the first stage of PharmaTher’s three-step commercialization plan: establishing the Center, then launching a controlled U.S. telehealth-enabled program, followed by scaling placements of 3D-printing systems with pharmacy partners. PD Labs will serve as the initial commercial hub, supporting fulfillment, standardized workflows, quality controls, traceability and patient-specific formulation development for medications and peptides.
According to PharmaTher, insights from this real-world environment are expected to guide onboarding and deployment across a broader PERSONALIZ3D™ network and support multiple potential revenue channels, including telehealth participation, 3D-printing system placements, consumables, software, services and formulation development.
PharmaTher (OTCQB: PHRRF) announced PERSONALIZ3D™, a personalized medicine platform that combines telehealth, pharmaceutical 3D printing and pharmacy fulfillment into an integrated ecosystem. The model centers on two business units: a telehealth platform linking patients with independent licensed healthcare providers and a North American network of pharmacy-based 3D-printing systems for compounded medicines.
PERSONALIZ3D™ will initially focus on peptides and other compounded prescriptions, offering customizable doses, combinations and dosage forms via digitally controlled pharmacy workflows with quality assurance and traceability. PharmaTher plans three rollout stages: establishing a Section 503A “Center of Excellence” pharmacy, launching a controlled telehealth program, and scaling via pharmaceutical 3D-printing system placements with U.S. Section 503A and Canadian compound pharmacies. The platform builds on PharmaTher’s collaboration with Craft Health’s CraftMake™ system and is structured to generate multiple recurring revenue streams.
PharmaTher (OTCQB: PHRRF) announced a collaboration with Craft Health to evaluate Craft Health's CraftMake™ GMP-ready pharmaceutical 3D printing platform for PharmaTher's Personaliz3D Peptides™ partner ecosystem. The parties will develop and test novel peptide formulations, personalized doses, combination products, controlled-release designs and differentiated dosage forms.
According to PharmaTher, the work will assess multiple peptides, including BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax, which were recently recommended by the FDA Pharmacy Compounding Advisory Committee for inclusion on the Section 503A Bulks List. The collaboration also contemplates a potential broader commercial relationship to deploy CraftMake™ with qualified Section 503A compounding pharmacies, combining PharmaTher's personalized peptide strategy with Craft Health's 3D printing hardware, software and printable formulations.
PharmaTher (CSE: PHRM, OTCQB: PHRRF) launched Personaliz3D Peptides™, a new division focused on personalized peptide therapies using 3D printing, artificial intelligence, telemedicine and qualified 503A compounding pharmacies. The division aims to integrate physician oversight, patient assessment and GMP-aligned manufacturing to enable patient-specific dosing, combination peptide formulations and alternative delivery formats such as tablets, gummies, oral films, gels, chews, suppositories and patches.
The launch follows recent positive, but non-binding, FDA Pharmacy Compounding Advisory Committee recommendations to add several peptides, including BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax, to the Section 503A Bulks List. PharmaTher plans a three-part strategy—Connect, Personalize and Deliver—centered on a new telemedicine platform at PersonalizedPeptidesRx.com, proprietary formulations, 3D printing systems, AI-assisted tools and a partnership-driven commercialization model with pharmacies, healthcare providers, researchers and pharmaceutical companies.
PharmaTher (CSE: PHRM, OTCQB: PHRRF) announced a collaboration with KetaMist inventor Dr. Curtis W. Cassidy to pursue U.S. FDA approval of the needle-free, patient-controlled ketamine platform for treatment-resistant depression and other conditions where ketamine has shown benefit.
KetaMist has reportedly been used in over 9,000 patient treatments, providing real-world experience that PharmaTher believes may support an efficient, potentially expedited FDA development strategy. PharmaTher will leverage its prior FDA-approved ketamine ANDA experience, despite having sold that ANDA in 2025, to guide regulatory, CMC and analytical aspects.
The collaboration includes a one-year evaluation period for PharmaTher to assess KetaMist and potentially negotiate further development and commercialization agreements. Near-term priorities include preparing an FDA meeting package, defining data and clinical requirements for a possible NDA, and evaluating the role of existing real-world data, while noting there is no assurance of FDA acceptance or approval.